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S U M M A R Y
Background: There are no data on the incidence and persistence of high-risk human papillomavirus (HR-
HPV) infections in female sex workers (FSWs). We aimed to describe and compare the rates of incidence
and persistence of HR-HPV infections in FSWs and women from the general population (WGP) who
attended healthcare facilities between May 2003 and December 2006 in Alicante, Spain.
Methods: Women with an established HR-HPV infection at study entry were evaluated for the analysis of
HR-HPV persistence, and those testing negative for HR-HPV infection at entry were evaluated for the
analysis of incidence. HR-HPV infection was determined by the Digene HC2 HR HPV DNA Test.
Results: A total of 736 women – 592 WGP and 144 FSWs – were followed for a median of 16.8 months.
Global incidence and persistence rates were 3.98 per 100 woman-years (95% conﬁdence interval (CI)
2.91–5.45) and 26.81 per 100 woman-years (95% CI 20.08–35.79), respectively. In the multivariate
analysis, only commercial sex work was associated with a statistically signiﬁcant higher incidence
(relative risk (RR) 4.72, 95% CI 2.45–9.09) and persistence (RR 1.93, 95% CI 1.08–3.46) of HR-HPV
infection.
Conclusions: Our data show that FSWs have both a higher incidence and a higher persistence of HR-HPV
than WGP and should be prioritized in HPV-related cancer screening programs.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Human papillomavirus (HPV) infection is the most frequent
sexually transmitted infection (STI) worldwide. High-risk HPV
(HR-HPV) is the main cause of cervical cancer.1 Population groups
with higher prevalences of infection, like women who are
incarcerated or female sex workers (FSWs), usually have sexual
risk behaviours.2–4 In women in the general population (WGP),
over half clear the virus spontaneously within a year of contracting
the infection. A higher risk of developing cervical cancer exists only
in the small proportion of cases with persistent infection, and in
the presence of other co-factors like oral contraceptive use,
smoking, or high parity.5 Trottier et al. recently reported that
infection with multiple HPV types is associated with longer
persistence of HPV infection, but that this is not the case for either
age or number of sexual partners.6 The prevalence of infection
includes all those established cases that do not clear spontane-
ously, as well as all incident cases. Accordingly, HPV prevalence is* Corresponding author. Tel.: +34 918222921; Fax: +34 913877815.
E-mail address: cgonzalezb@isciii.es (C. Gonza´lez).
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the persistence of infection. In comparison to prevalence studies,
fewer studies have been carried out on the incidence of HR-HVP
infection in WGP and none in the population in Spain. To our
knowledge, there have been no publications on the incidence and
persistence of global HR-HPV infection in FSWs.
The aim of this study was to describe and compare the
incidence and persistence of HR-HPV infections in FSWs and in
WGP who attended a healthcare facility between May 2003 and
December 2006 in the city of Alicante, Spain.
2. Methods
2.1. Study population
We conducted a prospective study with a cohort of WGP and
FSWs recruited at two sites in the city of Alicante, Spain. WGP were
recruited at a family planning clinic and FSWs at the Center for
AIDS Information and Prevention (CIPS). Both health facilities are
free of charge to all women, including immigrant women
irrespective of their legal and administrative status. Women were
invited to participate in the study between May 2003 andses. Published by Elsevier Ltd. All rights reserved.
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clinically indicated, up to December 2006. Characteristics of each
of the recruitment sites and baseline HR-HPV prevalence for WGP
and FSWs have been described previously,3,7 and are also
presented in Table 1. For the purpose of these analyses, only
women who had at least two HR-HPV test results separated by a
minimum of approximately 6 months were included. Some
women made more visits to the clinic, but we only analyzed the
incidence and persistence between the ﬁrst two visits. Figure 1
shows the number of women participating in each of the analyses;
women with an established HR-HPV infection at study entry were
evaluated for the analysis of HR-HPV persistence, and those testing
negative for HR-HPV infection at study entry were evaluated for
the analysis of HR-HPV incidence. We considered incident
infections as those occurring in women whose sample tested
HR-HPV-positive following an initial sample that tested negative.
We considered persistent infections as those occurring in women
whose sample tested HR-HPV-positive following an initial sample
that tested positive. Additional analyses were done to look for
statistically signiﬁcant differences in the socio-demographic
characteristics, sexual behaviors, and HPV prevalence betweenTable 1
Characteristics of study subjects at baseline and follow-up
WGP 
Baseline Follow-up p-Value Baseline 
n (%) n (%) n (%) 
(n = 1011) (n = 592) (n = 549) 
Age 0.0222 
25 years 274 (27.1) 123 (20.8) 185 (33.7) 
26–35 years 367 (36.3) 217 (36.7) 228 (41.5) 
36 years 366 (36.2) 250 (42.2) 134 (24.4) 
Unknown 4 (0.4) 2 (0.3) 2 (0.4) 
Area of origin 0.8964 
Spain 841 (83.2) 501 (84.6) 87 (15.8) 
Latin America 122 (12.1) 66 (11.1) 303 (55.2) 
Europe 32 (3.2) 17 (2.9) 91 (16.6) 
Africa/Asia 16 (1.6) 8 (1.4) 68 (12.4) 
Educational level 0.0572 
None 62 (6.1) 33 (5.6) 38 (6.9) 
Primary education 344 (34.0) 195 (32.9) 419 (76.3) 
High school 604 (59.7) 358 (60.5) 50 (9.1) 
Unknown 1 (0.1) 6 (1.0) 42 (7.7) 
Number of lifetime
sex partners
0.9284 
5 903 (89.3) 528 (89.2) 235 (42.8) 
>5 107 (10.6) 63 (10.6) 19 (3.5) 
Unknown 1 (0.1) 1 (0.2) 295 (53.7) 
Marital status 0.2208 
Single 370 (36.6) 196 (33.1) 300 (54.6) 
Married 464 (45.9) 301 (50.8) 54 (9.8) 
Lives with partner 101 (10.0) 49 (8.3) 63 (11.5) 
Separated/
divorced/widow
76 (7.5) 46 (7.8) 129 (23.5) 
Unknown 0 0 3 (0.5) 
Age at ﬁrst sexual
intercourse,
median (range)
18 (17–20) 18 (17–20) - 17 (15–18) 
Unknown 1 0 62 
Smoking in last year 0.7484 
No 516 (51.0) 312 (52.7) 268 (48.8) 
Yes 494 (48.9) 279 (47.1) 242 (44.1) 
Unknown 1 (0.1) 1 (0.2) 39 (7.1) 
HIV result 0.0894 
Negative 448 (44.3) 271 (45.8) 293 (53.4) 
Positive 3 (0.3) 2 (0.3) 16 (2.9) 
Unknown 560 (55.4) 319 (53.9) 240 (43.7) 
Duration of
follow-up (months),
median (range)
17.7 (14–26) 14.2 (11.5–1
WGP, women from the general population; FSWs, female sex workers.women who failed to return and those who were followed up,
stratiﬁed by center.
The two dependent variables were incident and persistent HR-
HPV infections determined by the Digene Hybrid Capture 2, High-
Risk HPV DNA Test (HC2 HR HPV DNA Test; Qiagen, Germany).
Detection of HR-HPV DNA in a woman who had a negative HR-HPV
DNA test at study entry was considered to be an incident infection.
Persistent infections were those cases that tested positive both at
study entry and during follow-up. The main independent variable,
being a FSW as compared to a WGP, was ascertained from the
recruitment site; FSWs were recruited at a FSW opt-in specialist
clinic with a long-standing tradition of treating FSWs, and WGP
from a family planning center where they were not speciﬁcally
asked whether they had ever exchanged sex for money. Most of the
women from the general population in Alicante go to family
planning centers for gynecological and routine exams. We also
collected information on age at entry (25, 26–35, 36 years, and
unknown), age at ﬁrst sexual intercourse (18, 19 years, and
unknown), area of origin (Spain, Latin America, Europe, and Africa/
Asia; these last two were recoded as ‘other’ because of the small
number of people from these regions), educational level (none,FSWs Total
Follow-up p-Value Baseline Follow-up p-Value
n (%) n (%) n (%)
(n = 144) (n = 1560) (n = 736)
0.4799 0.0039
47 (32.6) 459 (29.4) 170 (23.1)
63 (43.8) 595 (38.1) 280 (38.0)
32 (22.2) 500 (32.1) 282 (38.3)
2 (1.4) 6 (0.4) 4 (0.5)
0.0134 0.0000
21 (14.6) 928 (59.5) 522 (70.9)
76 (52.8) 425 (27.2) 142 (19.3)
15 (10.4) 123 (7.9) 32 (4.3)
32 (22.2) 84 (5.4) 40 (5.4)
0.0000 0.0000
14 (9.7) 100 (6.4) 47 (6.4)
44 (30.6) 763 (48.9) 239 (32.5)
73 (50.7) 654 (41.9) 431 (58.6)
13 (9.0) 43 (2.8) 19 (2.6)
0.4314 0.0001
56 (38.9) 1138 (72.9) 584 (79.3)
3 (2.1) 126 (8.1) 66 (9.0)
85 (59.0) 296 (19.0) 86 (11.7)
0.8443 0.0001
75 (52.1) 670 (42.9) 271 (36.8)
17 (11.8) 518 (33.2) 318 (43.2)
17 (11.8) 164 (10.5) 66 (9.0)
35 (24.3) 205 (13.1) 81 (11.0)
0 3 (0.2) 0
16 (14–17) - 18 (16–19) 18 (16–19) -
15 63 15
0.0074 0.0002
69 (47.9) 784 (50.3) 381 (51.8)
61 (42.4) 736 (47.2) 340 (46.2)
14 (9.7) 40 (2.6) 15 (2.0)
0.1095 0.1870
69 (47.9) 741 (47.5) 340 (46.2)
1 (0.7) 19 (1.2) 3 (0.4)
74 (51.4) 800 (51.3) 393 (53.4)
6.7) 16.8 (13.4–23.2)
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Figure 1. Flow chart of participants (WGP: women from the general population; FSWs: female sex workers).
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lives with partner, separated/divorced/widowed, and unknown),
number of life-time private sexual partners (5, > 5, and
unknown), smoking (no, yes, and unknown), and HIV status
(negative, positive, and unknown). HIV status was self-reported
for WGP recruited at the family planning center, and an HIV test
was done for FSWs at the Center for AIDS Information and
Prevention.
All the women who agreed to participate in the study gave oral
consent to an informed consent statement which was approved by
the Ethics Committee of the Universidad Miguel Herna´ndez de
Elche (Alicante, Spain). The present study was carried out before
the new law approved in Spain in 2007 in relation to biomedical
research, hence oral consent was allowed.
2.2. High-risk HPV detection
HR-HPV infection was determined by the HC2 HR HPV DNA
Test, which identiﬁes types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56,
58, 59, and 68. All cervical samples were taken using a cervical
brush and placed in Digene Specimen Transport Medium and
stored at 20 8C until required for testing. The HC2 HR HPV DNA
Test was performed following the manufacturer’s instructions.
In brief, the exfoliated cells are ﬁrst treated with alkalinedenaturation reagent, and the processed samples are hybridized
under high-stringency conditions. Positive specimens are
detected by binding the hybridization complexes onto the
surface of a microplate well coated with monoclonal antibodies
speciﬁc to RNA–DNA hybrids. Immobilized hybrids are detected
by the addition of an alkaline phosphatase-conjugated antibody
to RNA–DNA hybrids, followed by the addition of a chemilumi-
nescent substrate. Samples were analyzed at the National Center
of Microbiology in Madrid, Spain.
2.3. Statistical methods
Descriptive analyses of demographic characteristics and clinical
parameters were carried out using frequency distributions or
median and interquartile ranges (IQR) as appropriate. Baseline
characteristics of women who returned to the recruiting sites for a
second visit were compared to those who were lost to follow-up.
Differences were tested by Mann–Whitney U-test and Chi-square
test as appropriate. We calculated the HR-HPV incidence and
persistence rates as the number of events divided by the total
number of woman-years of follow-up. Analyses using woman-
months were also performed. The date of administrative censoring
was December 2006. We modeled relative rates by multivariate
Poisson regression analyses using a forward approach with all the
C. Gonza´lez et al. / International Journal of Infectious Diseases 15 (2011) e688–e694 e691variables of the study. Analyses were carried out in STATA 10
(StataCorp LP, College Station, TX, USA).
3. Results
The cohort included 736 women: 592 WGP who were followed
for an average of 17.7 months (IQR 14–26) and 144 FSWs who were
followed for a median of 14.2 months (IQR 11.5–16.7). Socio-
demographic and sexual behavior characteristics of the women are
shown in Table 1. The median age at study entry was 34 years (IQR
27–41) in WGP and 29 years (IQR 24–35) in FSWs. Overall, 501
(84.6%) WGP were Spanish and 76 (52.8%) FSWs were Latin
American. A total of 528 (89.2%) WGP reported fewer than ﬁve
lifetime sexual partners and 85 (59%) FSWs did not report their
number of lifetime sexual partners. Median age at ﬁrst sexual
intercourse was 18 years (IQR 17–20) in WGP and 16 years (IQR
14–17) in FSWs. Self-reported prevalence of HIV infection in the
273 WGP for whom this information was available was 0.3%,
versus 0.7% in 70 FSWs. The median time between HR-HPV test
results was 16.8 months (IQR 13.4–23.2) for all women.
Approximately 76.5% of WGP had used condoms sometime in
the past, and 32.7% had used them in the 6 months before the ﬁrst
visit. In the case of FSWs, 99.2% had used condoms in the past and
in the last 6 months. Of the FSWs who had used condoms both in
the last 6 months and previously, 94.4% used them always or
almost always in vaginal coitus with clients, and 10.7% did so with
their regular partners.
We analyzed differences between women who attended only
one visit and those who were followed on more than one occasion.Table 2
Incidence rates of HR-HPV infection
Person-years Num
WGP FSWs WGP
Age
25 years 171.64 26.27 6 
26–35 years 336.23 46.58 12 
36 years 365.22 28.58 7 
Unknown 2.20 2.26 0 
Area of origin
Spain 750.22 15.93 22 
Latin America 85.16 57.18 3 
Other 39.91 30.58 0 
Educational level
None 56.34 7.20 0 
Primary education 293.68 37.72 7 
High school 514.32 47.94 18 
Unknown 10.94 10.84 0 
Number of lifetime sex partners
5 794.57 38.02 23 
>5 78.65 3.37 2 
Unknown 2.06 62.30 0 
Marital status
Single 278.60 54.34 9 
Married 479.07 11.97 10 
Lives with partner 58.25 12.86 3 
Separated/divorced/widowed 59.37 24.52 3 
Smoking in last year
No 463.87 53.10 13 
Yes 409.60 42.23 12 
Unknown 1.81 - 0 
HIV result
Negative 394.42 46.50 8 
Positive 3.81 - 0 
Unknown 477.06 57.19 17 
Age at ﬁrst sexual intercourse
18 years 524.36 78.77 18 
19 years 350.93 17.03 7 
Unknown - 7.89 - 
HR-HPV, high-risk human papillomavirus; CI, conﬁdence interval; WGP, women from Among FSWs, 110 made only one visit and their HR-HPV
prevalence was 27.2%, and 59 had made more than one visit
and their HR-HPV prevalence was 40.7%; this difference was
statistically signiﬁcant (p = 0.003). The same pattern was observed
in WGP: 36 made only one visit and their HR-HPV prevalence was
8.6%, and 66 were followed up and their HR-HPV prevalence was
11.1%; however, the difference in this latter case was not
statistically signiﬁcant (p = 0.198). The proportion of WGP over
36 years of age was higher among those returning for a second visit
(42.2% vs. 27.6%, p < 0.001) than those who came only once. The
percentage of married WGP was higher in those who were
followed at a second visit than in those who came only once (50.8%
vs. 38.8%, p = 0.001).
3.1. Incidence of HR-HPV infection
The overall incidence rate was 3.98 per 100 woman-years (95%
CI 2.91–5.45) or 0.33 per 100 woman-months (95% CI 0.24–0.45).
This rate was lower in WGP (2.85 per 100 woman-years (95% CI
1.92–4.22) or 0.23 per 100 woman-months (95% CI 0.16–0.35))
than in FSWs (13.5 per 100 woman-years (95% CI 7.99–22.79) or
1.12 per 100 woman-months (95% CI 0.66–1.90)). Table 2 shows
the rates of incidence of HR-HPV infection per 100 woman-years
for WGP and FSWs.
The crude relative risks (RR) of HR-HPV incidence are presented
in Table 3. The risk of infection was almost ﬁve times higher in
FSWs than in WGP (RR 4.72, 95% CI 2.45–9.09). The risk of infection
was lower in Spanish women (RR 0.34, 95% CI 0.16–0.68) than in
Latin Americans, and was lower in married women (RR 0.43, 95% CIber of incident
cases
Rate/100 woman-years (95% CI)
 FSWs WGP FSWs
4 3.49 (1.57–7.78) 15.22 (5.71–40.56)
6 3.56 (2.02–6.28) 12.87 (5.78–28.66)
3 1.91 (0.91–4.02) 10.49 (3.38–32.53)
1 - 44.23 (6.23–314.01)
0 2.93 (1.93–4.45) -
9 3.52 (1.13–10.92) 15.73 (8.18–30.24)
5 - 16.34 (6.80–39.27)
2 - 27.77 (6.94–111.04)
3 2.38 (1.13–4.99) 7.95 (2.56–24.650)
8 3.49 (2.20–5.55) 16.68 (8.34–33.36)
1 - 9.22 (1.29–65.47)
3 2.89 (1.92–4.35) 7.89 (2.54–24.46)
2 2.54 (0.63–10.16) 59.20 (14.80–236.31)
9 - 14.44 (7.51–27.76)
8 3.23 (1.68–6.20) 14.72 (7.36–29.43)
1 2.08 (1.12–3.87) 8.35 (1.17–59.29)
1 5.14 (1.66–15.96) 7.77 (1.09–55.18)
4 5.05 (1.62–15.66) 16.30 (6.12–43.45)
9 2.80 (1.62–4.82) 16.94 (8.81–32.57)
3 2.92 (1.66–5.15) 7.10 (2.29–22.02)
- - -
5 2.02 (1.01–4.05) 10.75 (4.47–25.83)
- - -
9 3.56 (2.21–5.73) 15.73 (8.18–30.24)
11 3.43 (2.16–5.44) 13.96 (7.73–25.21)
2 1.99 (0.95–4.18) 11.73 (2.93–46.93)
1 - 12.67 (1.78–89.96)
the general population; FSWs, female sex workers.
Table 3
Univariate analyses of the relative risk of HR-HPV incidence
RR (95% CI)
Age
25 years 1
26–35 years 0.93 (0.42–2.01)
36 years 0.50 (0.20–1.20)
Unknown 4.43 (0.56–34.64)
Area of origin a
Spain 0.34 (0.16–0.68)
Latin America 1
Others 0.84 (0.29–2.38)
Educational level
None 1
Primary education 0.95 (0.21–4.37)
High School 1.46 (0.34–6.19)
Unknown 1.45 (0.13–16.08)
Number of lifetime sex partners
5 1
>5 1.56 (0.54–4.47)
Unknown 4.47 (2.09–9.55)
Marital status a
Single 1
Married 0.43 (0.20–0.93)
Lives with partner 1.10 (0.37–3.27)
Separated/divorced/widowed 1.63 (0.67–3.94)
Smoking in last year
No 1
Yes 0.78 (0.40–1.50)
Unknown -
HIV result
Negative 1
Positive -
Unknown 1.65 (0.84–3.21)
Age at ﬁrst sexual intercourse
18 years 1
19 years 0.50 (0.24–1.07)
Unknown 2.63 (0.35–19.34)
Recruitment b
WGP 1
FSWs 4.72 (2.45–9.09)
HR-HPV, high-risk human papillomavirus; RR, relative risk; CI, conﬁdence interval;
WGP, women from the general population; FSWs, female sex workers.
a p-Value of homogeneity < 0.05.
b p-Value of homogeneity < 0.001.
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remained associated with the incidence of HR-HPV infection in the
multivariate analysis was engaging in prostitution (RR 4.72, 95% CI
2.45–9.09); the relative risk of infection in FSWs was the same in
the multivariate analysis as in the univariate analysis.
3.2. Persistence of HR-HPV infection
The overall rate of persistence was 26.81 per 100 woman-years
(95% CI 20.08–35.79) or 2.23 per 100 woman-months (95% CI 1.67–
2.98). Similar to the results for incidence rates, persistence was
lower in WGP (19.8 per 100 woman-years (95% CI 12.88–30.31) or
1.64 per 100 woman-months (95% CI 1.07–2.52)) than in FSWs
(38.28 per 100 woman-years (95% CI 25.86–56.65) or 3.19 per 100
woman-months (95% CI 2.15–4.72)).
Table 4 shows the rates of persistence of HPV infection per 100
woman-years for WGP and FSWs.
The crude relative risks of HR-HPV persistence are presented in
Table 5. The risk of persistence was lower in Spanish women (RR
0.71, 95% CI 0.37–1.36) than in Latin Americans, and was lower in
married women (RR 0.77, 95% CI 0.34–1.72) than in those who
were single, although these differences were not statistically
signiﬁcant. Women who engaged in prostitution had nearly double
the risk of persistent HR-HPV infection (RR 1.93, 95% CI 1.08–3.46),
a risk that was maintained in the multivariate analysis with the
same relative risk.4. Discussion
The rates of HR-HPV incidence and persistence were signiﬁ-
cantly higher in FSWs than in WGP, differences that were more
marked in the case of incidence than persistence of HR-HPV
infection. The incidence of HR-HPV in FSWs was 13.51 per 100
woman-years and in WGP was 2.85 per 100 woman-years. The
persistence of HR-HPV in FSWs was 38.28 per 100 woman-years
and in WGP was 19.76 per 100 woman-years. The only risk factor
identiﬁed in this study for the incidence and persistence of HR-HPV
infection was engaging in prostitution.
Prostitution was associated with a ﬁve-fold greater risk of
acquiring HR-HPV than in WGP. In fact, the only risk factor
associated with the incidence of HR-HPV found in this work was
being a FSW. Although a higher incidence in Latin American and
single women was found in the univariate analysis, these
differences disappeared in the multivariate analysis since they
reﬂect characteristics of FSWs. The only risk factor associated with
the persistence of HR-HPV infection was engaging in prostitution.
The risk of persistent infection in FSWs was double that in WGP.
These data suggest that, although the incidence of infection seems
to be more closely associated with sexual risk behaviors, these
appear to be less important in explaining the persistence of
infection. However this ﬁnding should be interpreted with caution
since we are not assessing the persistence of incident infections but
of established ones.
As far as we know, these are the ﬁrst data published on the
incidence and persistence of HR-HPV in both FSWs and WGP in
Spain, so they cannot be compared with ﬁndings of previous
publications in our country. The high incidence in FSWs compared
with WGP could be expected, but there has not yet been any paper
published on this. The incidence of HR-HPV infections in WGP in
our study from Alicante is, nevertheless, lower than that reported
by authors from the USA, Canada, and other European countries.
The cumulative incidence of HR-HPV infection in young women in
the USA was around 40% at 3 years8,9 and 32.3% at 2 years.10,11 In a
gynecology center in Arizona, the incidence rate for any type of
HPV in women between age 18 and 35 years was 2.9% per month,
with higher proportions for oncogenic types.12 In Canada, the HR-
HPV incidence rate in university women was 14 per 1000 woman-
months.13 In Brazil, the incidence of infection was 6.8 per 1000
woman-months (95% CI 5.4–8.4) in women of low socioeconomic
status aged between 18 and 60 years.14 In the former Soviet Union,
the overall rate of incident HR-HPV infections was 1.0 per 100
woman-months at risk.15 In Denmark, the overall 2-year incidence
of HR-HPV infection in initially HPV-negative women was 12.8%
(95% CI 12.0–13.6).16 Although no HPV incidence data have
previously been published in Spain, the prevalence of HPV
infection in Spain is one of the lowest in the world; de Sanjose´
et al., in the only population-based work to-date in Spain, reported
a prevalence of HPV infection in women in the general population
of 3%.17 Spain also has one of the lowest incidence rates of cervical
cancer, around 7%.1
With regard to persistence of HR-HPV infection, Franco et al.
observed that 61% (95% CI 54–69) of a cohort of women in Brazil
remained infected at 6 months, and only 35% (95% CI 27–42) after
12 months.14 Sellors et al. reported a persistence of 48% (26/54)
after a median of 14 months in women in Canada.18 In a
gynecology center in Arizona, the percentage of persistent
infection from any type of HPV was 50.3% in women who had
had more than two visits.12 The persistence of HR-HPV infection in
WGP in our study is lower than that described in previously
published studies.12,14,18
Our ﬁndings on the incidence or persistence of HR-HPV in FSWs
cannot be compared with other studies as there are no previous
publications in this group of women; the sexual and reproductive
Table 4
Persistence of HR-HPV infection
Person-years Number of persistent
cases
Rate/100 woman-years (95% CI)
WGP FSWs WGP FSWs WGP FSWs
Age
25 years 32.91 30.98 8 14 24.30 (12.15–48.59) 45.18 (26.76–76.30)
26–35 years 28.81 25.91 4 8 13.88 (5.21–36.98) 30.87 (15.43–61.73)
36 years 44.52 8.41 9 3 20.21 (10.51–38.84) 35.65 (11.49–110.54)
Unknown - - - - - -
Area of origin
Spain 75.89 10.85 15 3 19.76 (11.91–32.78) 27.63 (8.91–85.67)
Latin America 28.18 33.59 4 14 14.19 (5.32–37.80) 41.66 (24.67–70.35)
Other 2.17 20.84 2 8 92.12 (23.04–368.37) 38.36 (19.18–76.72)
Educational level
None 1.84 9.26 0 2 - 21.58 (5.39–86.30)
Primary education 32.04 13.11 7 5 21.84 (10.41–45.82) 38.13 (15.87–91.62)
High School 72.36 36.04 14 17 19.34 (11.45–32.66) 47.16 (29.32–75.87)
Unknown - 6.88 - 1 - 14.51 (2.04–103.05)
Number of lifetime sex partners
5 84.88 26.21 13 10 15.31 (8.89–26.37) 38.14 (20.52–70.88)
>5 21.37 0.99 8 0 37.42 (18.71–74.83) -
Unknown - 38.09 - 15 - 39.37 (23.73–65.31)
Marital status
Single 43.09 34.11 9 15 20.88 (10.86–40.13) 43.97 (26.50–72.93)
Married 26.21 7.08 4 4 15.25 (5.72–40.65) 56.42 (21.17–150.34)
Lives with partner 19.73 7.02 5 2 25.34 (10.54–60.88) 28.48 (7.12–113.89)
Separated/divorced/widowed 17.21 17.08 3 4 17.42 (5.62–54.04) 23.41 (8.78–62.38)
Smoking in last year
No 42.66 25.63 5 12 11.71 (4.87–28.15) 46.81 (26.58–82.42)
Yes 63.59 31.54 16 12 25.16 (15.41–41.07) 38.03 (21.60–66.97)
Unknown - - - - - -
HIV result
Negative 59.49 33.27 12 13 20.16 (11.45–35.51) 39.06 (22.68–67.28)
Positive - 1.26 - 0 - -
Unknown 46.75 30.76 9 12 19.24 (10.01–36.99) 38.99 (22.14–68.67)
Age at ﬁrst sexual intercourse
18 years 77.26 54.39 14 20 18.11 (10.73–30.59) 36.76 (23.72–56.99)
19 years 28.98 2.42 7 1 24.14 (11.51–50.65) 41.27 (5.81–292.99)
Unknown - 8.49 - 4 - 47.10 (17.67–125.50)
HR-HPV, high-risk human papillomavirus; CI, conﬁdence interval; WGP, women from the general population; FSWs, female sex workers.
Table 5
Univariate analyses of the relative risk of HR-HPV persistence
RR (95% CI)
Age
25 years 1
26–35 years 0.63 (0.31–1.28)
36 years 0.65 (0.32–1.33)
Unknown -
Area of origin
Spain 0.71 (0.37–1.36)
Latin America 1
Other 1.49 (0.68–3.23)
Educational level
None 1
Primary education 1.47 (0.33–6.59)
High School 1.58 (0.38–6.64)
Unknown 0.80 (0.07–8.89)
Number of lifetime sex partners
5 1
>5 1.72 (0.77–3.86)
Unknown 1.90 (0.99–3.64)
Marital status
Single 1
Married 0.77 (0.34–1.72)
Lives with partner 0.84 (0.36–1.95)
Separated/divorced/widowed 0.65 (0.28–1.52)
Smoking in last year
No 1
Yes 1.18 (0.64–2.16)
Unknown -
HIV result
Negative 1
Positive -
Unknown 1.00 (0.56–1.79)
Table 5 (Continued )
RR (95% CI)
Age at ﬁrst sexual intercourse
18 years 1
19 years 0.98 (0.45–2.13)
Unknown 1.82 (0.64–5.14)
Recruitment a
WGP 1
FSWs 1.93 (1.08–3.46)
HR-HPV, high-risk human papillomavirus; RR, relative risk; CI, conﬁdence interval;
WGP, women from the general population; FSWs, female sex workers.
a p-Value of homogeneity < 0.05.
C. Gonza´lez et al. / International Journal of Infectious Diseases 15 (2011) e688–e694 e693health of FSWs has not been sufﬁciently studied. Analysis of
condom use in FSWs showed differences between their use with
clients and with regular partners. Condom use with clients was
nearly 100%, whereas the percentage using condoms with regular
partners was lower. Similar results have been reported by del Amo
et al. in the same cohort of FSWs in Alicante3 and by Belza et al. in a
study in FSWs in Madrid.19 Although condoms do not offer 100%
protection against HR-HPV, Winer et al. have described a reduced
risk associated with systematic use.20 Thus, in addition to insisting
on the need for consistent condom use with clients, the role of
private partners as sources of HR-HPV infection, as well as other
sexually transmitted infections, cannot be neglected.
The non-signiﬁcance of some of the risk factors in our work may
well have been due to the lack of statistical power, the main
limitation in this type of study. Losses to follow-up are particularly
high in FSWs, a group that is difﬁcult to retain in a follow-up study,
C. Gonza´lez et al. / International Journal of Infectious Diseases 15 (2011) e688–e694e694given their working, social, and legal characteristics. Persistent
infections may include the clearance of one HPV genotype together
with incident infection by another type. Unfortunately we did not
calculate type-speciﬁc incidence or persistence in this study.
Among FSWs, those with an established HR-HPV infection were
more likely to return for a second visit. Given the high losses to
follow-up in FSWs, the incidence estimates have to be interpreted
with caution, but highlight the higher incidence of HR-HPV in this
group; it is expected that HPV incidence may be even higher
among FSWs not accessing healthcare services.
In summary, these are the ﬁrst data published on the incidence
and persistence of HR-HPV in Spain and, to our knowledge, the ﬁrst
data published on these outcomes in FSWs. Our data show that
FSWs have both a higher incidence and a higher persistence of HR-
HPV than WGP, thus they should be prioritized in HPV-related
cancer screening programs. In this respect, supporting clinics that
treat the high-risk population are important in the ﬁght against
cervical cancer in vulnerable populations.
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